RU94012304A - Agent for hepatitis a and b treatment - Google Patents

Agent for hepatitis a and b treatment

Info

Publication number
RU94012304A
RU94012304A RU94012304/14A RU94012304A RU94012304A RU 94012304 A RU94012304 A RU 94012304A RU 94012304/14 A RU94012304/14 A RU 94012304/14A RU 94012304 A RU94012304 A RU 94012304A RU 94012304 A RU94012304 A RU 94012304A
Authority
RU
Russia
Prior art keywords
agent
sodium
acid
hepatitis
treatment
Prior art date
Application number
RU94012304/14A
Other languages
Russian (ru)
Other versions
RU2063230C1 (en
Inventor
Р.А. Султанов
Uz]
Original Assignee
Р.А. Султанов
Uz]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Р.А. Султанов, Uz] filed Critical Р.А. Султанов
Priority to RU9494012304A priority Critical patent/RU2063230C1/en
Application granted granted Critical
Publication of RU2063230C1 publication Critical patent/RU2063230C1/en
Publication of RU94012304A publication Critical patent/RU94012304A/en

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FIELD: medicine, pharmacy. SUBSTANCE: agent has the following components, mg: potassium dihydrogen phosphate, 5.5; sodium hydrogen phosphate, 40.0; sodium hydrocarbonate, 40.0; sodium chloride, 4.0; copper dichloride, 5.5; and boric acid, 5.0. Preparation normalizes acid-alkaline balance and does not exhibit by-side action. EFFECT: enhanced effectiveness of agent.

Claims (1)

Изобретение относится к медицине, а именно к созданию лекарственных средств для лечения гепатита А и В. Сущность изобретения состоит в том, что предложенное средство содержит, мг: калий фосфорно-кислый однозамещенный 5,5; натрий фосфорно-кислый двузамещенный 40,4; натрий бикарбонат 40,0; поваренная соль 4,0; двухлористая медь 5,5; борная кислота 5,0. Предложенный препарат восстанавливает и нормализует кислотно-щелочной баланс, не имеет побочных эффектов.The invention relates to medicine, namely to the creation of drugs for the treatment of hepatitis A and B. The essence of the invention lies in the fact that the proposed tool contains, mg: potassium phosphoric acid monosubstituted 5.5; sodium phosphoric acid disubstituted 40.4; sodium bicarbonate 40.0; sodium chloride 4.0; copper chloride 5.5; boric acid 5.0. The proposed drug restores and normalizes the acid-base balance, has no side effects.
RU9494012304A 1994-04-07 1994-04-07 Agent for hepatitis a and b treatment RU2063230C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU9494012304A RU2063230C1 (en) 1994-04-07 1994-04-07 Agent for hepatitis a and b treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU9494012304A RU2063230C1 (en) 1994-04-07 1994-04-07 Agent for hepatitis a and b treatment

Publications (2)

Publication Number Publication Date
RU2063230C1 RU2063230C1 (en) 1996-07-10
RU94012304A true RU94012304A (en) 1997-03-20

Family

ID=20154455

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9494012304A RU2063230C1 (en) 1994-04-07 1994-04-07 Agent for hepatitis a and b treatment

Country Status (1)

Country Link
RU (1) RU2063230C1 (en)

Also Published As

Publication number Publication date
RU2063230C1 (en) 1996-07-10

Similar Documents

Publication Publication Date Title
RU94032150A (en) Medicinal agent exhibiting delayed release of active-acting substance
CO4700482A1 (en) FORMULATIONS OF A MONOMER INSULIN ANALOG
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
RU94026283A (en) Pharmaceutical compound
RU92004521A (en) APPLICATION OF BISPHOSPHONATES AND EXTRACT OF PARASITIC Glands FOR THE TREATMENT OF OSTEOPOROSIS AND A KIT FOR TREATMENT
RU95109905A (en) Liquid, semisolid, solid, gel-like or paste-like compositions and a method of mouth cavity disease treatment
AU7443898A (en) Sonodynamic therapy using an ultrasound sensitizer compound
RU94041223A (en) Agent for motoneuron disease treatment
EA200000087A1 (en) EFFICIENCY EFFICIENCY IMPROVEMENT OF HYPERPROLIFERATIVE STATE THERAPY WITH THE HELP OF ANTIOXIDANT
DE69734734D1 (en) SATURATED 1,2-DITHIACHETEROCYCLIC COMPOUNDS CONTAINING ANTIVIRAL PHARMACEUTICAL PREPARATIONS
UY24308A1 (en) BINDER-FREE TABLETS CONTAINING TRAMADOL OR A SALT OF TRAMADOL, FOR ORAL ADMINISTRATION
DE3850007T2 (en) Tumor or cancer cell killing therapy and active substances that can be used accordingly.
DK0621775T3 (en) Peptide drug-containing pellets, their preparation and use.
RU95101385A (en) Products containing g-csf and tnf-binding protein
DE69422712T2 (en) TRIS-PLATINUM COMPLEXES
DK0476066T3 (en) Antiviral preparation containing 3-azido-2,3-dideoxy-5-methylcytidine
CO4940452A1 (en) CRYSTAL MODIFICATION OF AN ACTIVE MEDICINAL SUBSTANCE
RU94012304A (en) Agent for hepatitis a and b treatment
ITMI932189A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYL CARNOSINE FOR THE TREATMENT OF CATARACT
HUP9901935A2 (en) Dosage kit for targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
RU94045140A (en) Pharmaceutical composition for prophylaxis and treatment of viral diseases, method of its preparing and use of bradykinin antagonist or its physiologically tolerant salt as agent for prophylaxis and treatment of viral diseases
SE9504259D0 (en) Method and composition for removal of mercury released from amalgam in oral cavity
DK1096923T3 (en) Blisters containing a transdermal therapeutic system and a single dose administration form
RU93055556A (en) DRUG FOR TREATMENT OF MASTITA OF CATTLE "LIZOMAST"